Compare Gilead Sciences, Inc. (GILD) vs Mongodb Inc (MDB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Mongodb Inc — how do they compare? Gilead Sciences, Inc. trades at $151.13 (market cap $182.40B), while Mongodb Inc trades at $385.93 (market cap $29.24B). The key difference: Gilead Sciences, Inc. is far larger — about 6.2× Mongodb Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Mongodb Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Mongodb Inc for 46 Days on average.
| GILD | MDB | |
|---|---|---|
Market Cap | $182.40B | $29.24B |
Volume | 4,469,821 | 1,304,995 |
Sector | Health | Technology |
52-Week High | $155.80 | $472.29 |
52-Week Low | $116.74 | $225.95 |
Typical Hold Time | 111 Days | 46 Days |
Enterprise Value | $205.46B | $26.86B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $151.17, up 2.94% recently, with strong technical momentum and bullish moving averages. The company shows robust revenue growth to $29.44B in 2025 and beat earnings estimates in three consecutive quarters, though net income margin turned negative at -10.64% for 2026. Recent developments include expanded HIV drug access in Latin America via a PAHO partnership, positioning Gilead for growth in its core franchises.
Gilead presents a mixed outlook with solid operational cash flow and analyst bullishness (65.5% buy ratings) offset by profitability concerns and high debt levels. The stock's current price aligns with the consensus target of $151.57, suggesting limited near-term upside. Key risks include execution in oncology pipeline expansion and reliance on HIV treatment revenues amid competitive pressures.
MongoDB (MDB) trades at $385.93, up 6.31% in the last session, reflecting strong momentum. The stock is technically bullish, with the price above key moving averages, though oscillators are neutral. Fundamentally, revenue growth is robust, with sales rising from $874M in 2022 to $2.01B in 2025, but profitability remains a challenge with negative net income. Recent news highlights the CEO transition and new AI product launches, which have generated mixed market reactions.
The outlook is cautiously optimistic, driven by raised long-term revenue targets and AI-focused innovations, but risks include persistent unprofitability and executive turnover. Analyst consensus is strongly bullish with an $456.76 price target, suggesting potential upside, though high valuation multiples warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →
